Lung MRI for non-cancer lung disease (early IPF)
Official title: Magnetic Resonance Imaging of the Lung: Non-Oncological Applications
Run by Fondazione IRCCS Policlinico San Matteo di Pavia · NCT07493187 · Data updated 2026-11-12
This project will try using advanced lung MRI (with bronchoalveolar lavage when safe) to look for imaging and molecular signs in people with early-stage idiopathic pulmonary fibrosis (IPF).
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Pavia, Lombardy) |
| Status | Recruiting |
| Started | December 28, 2020 |
| Main results expected | April 28, 2026 |
| Study ends | April 28, 2026 |
| Registry record updated | March 25, 2026 |
| Trial ID | NCT07493187 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with a clinical and radiological diagnosis of early-stage idiopathic pulmonary fibrosis who can safely undergo MRI and bronchoalveolar lavage are ideal candidates.
✕Probably not a fit
People with advanced IPF, or anyone who has contraindications to MRI or bronchoalveolar lavage, likely will not benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational, single-center project using advanced magnetic resonance imaging of the lungs in patients with early-stage IPF. When clinically appropriate and safe, bronchoalveolar lavage samples will be collected to link imaging features with cellular and molecular signatures. The work is motivated by data suggesting IPF shows neoplasm-like molecular behavior, including signaling through receptors such as MET, and aims to find noninvasive imaging correlates of those processes. All procedures are performed at Fondazione IRCCS Policlinico San Matteo di Pavia and no investigational treatments are given.
Why it matters
Potential benefit: If successful, this approach could provide noninvasive ways to detect and monitor early IPF changes and help guide future targeted therapies.
How similar studies have gone: Advanced lung MRI and molecular profiling in IPF have shown promising preliminary results, but combining MRI with molecular markers like MET signaling is still relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical and radiological diagnosis of early-stage IPF Exclusion Criteria: * Absolute contraindications to bronchoalveolar lavage or magnetic resonance imaging
Where it's running
-
Fondazione IRCCS Policlinico San Matteo di Pavia
Pavia, Lombardy, Italy Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Telitacicept for primary Sjögren’s with interstitial lung disease
This study tests whether Telitacicept helps people with primary Sjögren’s syndrome and interstitial lung disease compared with standard immunosuppressants.
-
Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients
This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.
-
Treprostinil Palmitil Inhalation Powder for Progressive Pulmonary Fibrosis
A 52-week study will test whether once-daily Treprostinil Palmitil Inhalation Powder helps lung function in adults with progressive pulmonary fibrosis compared to placebo.
-
Treatment Response in Myositis-Associated RP-ILD in Adults
This study tests how people with myositis and rapidly progressing interstitial lung disease respond to an immunosuppressant treatment approach.
-
AccuPulmo CT Portal for Detecting Pulmonary Fibrosis on Chest CT
This study tests how well the AccuPulmo CT Portal can identify pulmonary fibrosis on existing chest CT scans from adults at Taichung Veterans General Hospital.
-
See if 18F-FAPI-74 PET/CT can better detect fibrosis in heart and lung disease
Researchers are testing a new PET/CT tracer, 18F-FAPI-74, to see if it can reveal early fibrotic changes in people with heart and lung diseases who are at risk for tissue scarring.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.